Long-Term Urodynamic Effects
of Finasteride in Benign
Prostatic Hyperplasia:
A Pilot Study

Kirby, Roger; Vale, Justin; Bryan, J.; Holmes, Kate; Webb, Judith A. W.

doi:10.1159/000474256

Cited by 26 publications

(14 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Possibly with the medication continuation it would be seen a difference in the cellularity between the groups on study. Other studies have shown that is necessary a six month therapy with finasteride to elicit a tissue response 21 , what justifies the observations in this experiment.…”

Section: Discussionsupporting

confidence: 80%

Effect of finasteride on serum prostate-specific antigen (PSA) and on prostate of hamster Mesocricetus auratus (hMa)

et al. 2010

View full text Add to dashboard Cite

Effect of finasteride on serum prostate-specific antigen (PSA) and on prostate of hamster Mesocricetus auratus (hMa) ABSTRACT Purpose: Evaluate the effects of finasteride on the serum PSA and on the prostate of hamster-Mesocricetus auratus(hMa). Methods: Twenty hMa male adults were split in groups control and experimental (n=10). Animals of the experimental group received 7.14ng/mL of finasteride, subcutaneously (SC) on the back three times per week, during 90 days. The finasteride dose was equivalent to 5.0mg administered to a 70kg man. At the end of the experiment the mean age for the animals in the control group was 15.2±1.13months and for the experimental group was 17.7±0.67 months. There was a statistically significant difference between mean ages of both groups (t value=5.98; p=0.001). The animals of the control group weighted 129.0±18.8g and the experimental group weighted 145.0±15.5g, t=1.88 e p=0.0514. The serum PSA was assessed through ELISA method. Prostates of those animals were collected and processed to histology and morphometry: the diameter of the acinous glands and the acinous epithelium, apoptosis, AgNORs and cellularity were assessed in both groups. Results: Serum PSA decreased in the experimental group, 0.003ng/mL versus 0.763ng/mL, H= 7.982 e p= 0.0047. Decrease in the acinous area occurred in animals that received finasteride, 238.000±24.600 µm 2 versus 398.600±55.320 µm 2 ; t= 2.653; p= 0.0122. A remarkable decrease in the area of the acinous epithelium occurred in the animals that received finasteride, 111.900±12.820 µm 2 versus 160.400±18.430 µm 2 t= 2.162; p= 0.0361. AgNORs were less expressed in finasteride treated animals, 2.846±0.877 versus 3.68 ±1.07 argyrophilic clusters for µm 2 , p= < 0.0001. Apoptosis was more intense in the experimental group, 53.62±1.389 than in controls, 14.76 ± 2.137, p= 0.0408. However, there was no statistical difference in the cellularity between both groups, 74.75±5.5 cells, in controls versus 65.07±13.24, in treated animals, p=0.5105. Conclusions: Use of finasteride decreased serum PSA and several histological parameters of the Hamster's prostate, such as lumen area, acinous and epithelium area, and AgNORs expression. Finasteride increased apoptosis in the prostate acinous cells although no significant difference in the cellularity could be found between the two groups of animals under study.

show abstract

Section: Discussionsupporting

confidence: 80%

Effect of finasteride on serum prostate-specific antigen (PSA) and on prostate of hamster Mesocricetus auratus (hMa)

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Based on the aforementioned background, it is rare that patients with LUTS as a result of BPH receive treatment with 5‐ARI alone, and there are few studies that evaluated the efficacy of monotherapy with 5‐ARI. The recent guidelines stated that the precise mechanism of action of 5‐ARI in disease progression is most likely attributable to reduction of bladder outlet resistance based on a few reports with finasteride . Regarding one of three long‐term studies with finasteride, Kirby et al .…”

Section: Introductionmentioning

confidence: 99%

Effects of dutasteride on storage and voiding symptoms in male patients with lower urinary tract symptoms as a result of benign prostatic obstruction: The 1‐year outcomes from a prospective urodynamic study

et al. 2014

View full text Add to dashboard Cite

Abbreviations & Acronyms 5-ARI = 5-α reductase inhibitors α1-blockers = α1-adrenergic receptor blockers BII = benign prostatic hyperplasia impact index BOO = bladder outlet obstruction BOOI = bladder outlet obstruction index BPH = benign prostatic hyperplasia CMG = cystometrogram CombAT = Combination of Avodart and Tamsulosin FDV = first desire to void IDC = involuntary detrusor contraction IPSS = International Prostate Symptom Score IPSS-QOL = International Prostate Symptom Score quality of life LUTS = lower urinary tract symptoms MCC = maximum cystometric capacity OABSS = Overactive Bladder Symptom Score PdetQmax = detrusor pressure at maximum flow rate PFS = pressure flow study PSA = prostate-specific antigen Qmax = maximum flow rate UDS = urodynamic study Objectives: To investigate the effects of dutasteride 0.5 mg once daily for 12 months on lower urinary tract symptoms in treatment-naïve patients with benign prostatic hyperplasia. Methods:The present open-label, single-center, prospective study recruited 105 outpatients. International Prostate Symptom Score, Overactive Bladder Symptom Score, quality of life score testing and Benign Prostatic Hyperplasia Impact Index were used for assessing subjective symptoms. Urodynamic study including uroflowmetry, cystometry and pressure flow study were carried out to evaluate objective symptoms. As parameters of storage function, first desire to void, maximum cystometric capacity and occurrence of involuntary detrusor contraction were measured, whereas maximum flow rate, detrusor pressure at maximum flow rate, post-void residual urine and bladder outlet obstruction index were assessed as parameters of voiding function. Wilcoxon's rank-sum test, Student's t-test and the χ 2 -test were carried out to evaluate changes in subjective and objective symptoms. Results: A total of 97 patients with a mean age of 68.8 years and mean prostate volume of 57.6 mL were included in the analysis. Subjective symptom parameters improved significantly after 2 months, and progressively improved until after 12 months. Significant improvements in storage function objective parameters and voiding function objective parameters were observed after 6 months, and further improvements were obtained after 12 months. Conclusions: Dutasteride is effective in relieving lower urinary tract symptoms by improving storage and voiding function, as well as subjective symptoms in patients with benign prostatic hyperplasia.

show abstract

“…Longer term studies suggest that these results last up to three years and are associated with reduced voiding pressures consistent with an improvement in bladder outflow obstruction 6. The only side effect of finasteride seems to be a 3-5% incidence of sexual dysfunction.…”

Section: Drug and Interventional Alternativesmentioning

confidence: 87%

Controversies in Management: Urologists must grasp the future

Kirby

1994

BMJ

View full text Add to dashboard Cite

Long-Term Urodynamic Effects of Finasteride in Benign Prostatic Hyperplasia: A Pilot Study

Cited by 26 publications

References 16 publications

Effect of finasteride on serum prostate-specific antigen (PSA) and on prostate of hamster Mesocricetus auratus (hMa)

Effect of finasteride on serum prostate-specific antigen (PSA) and on prostate of hamster Mesocricetus auratus (hMa)

Effects of dutasteride on storage and voiding symptoms in male patients with lower urinary tract symptoms as a result of benign prostatic obstruction: The 1‐year outcomes from a prospective urodynamic study

Controversies in Management: Urologists must grasp the future

Contact Info

Product

Resources

About